Sensamide inhibitor of DNA repair data

OXGN (New York) said in an analyst conference call that a Phase I Swedish trial in 17 of 24 patients who have been followed for a year or more shows median survival of a year and five months. Ten of the 24 patients are still alive. These survival rates are two to three times that of historic controls, the company said. ...